Conference Details - Agenda
View all Conferences
This activity is approved for AMA PRA Category 1 Credit™
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.
Continuing Education Information
Physicians: Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.This activity is approved for AMA PRA Category 1 Credit™
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.
Fifth Annual Symposium on the Future of Lung Cancer
Hyatt Regency Reston
Reston, VA
December 6, 2008
Saturday, Dec 6, 2008
| 7:30 am | Registration and Continental Breakfast |
| 8:00 am | Welcome and Introductions Thomas Lynch, Alexander Spira |
| 8:05 am | Presession Survey |
| Developments in Early-Stage and Locally Advanced NSCLC Moderator: Thomas Lynch |
|
| 8:10 am | Implications of Changes Proposed by the IASLC Staging Project Harvey I. Pass |
| 8:30 am | Question-and-Answer Session |
| 8:35 am | Evolving Role of Video-Assisted Thorascopic Surgery in Stage I/II Disease Christopher Morse |
| 8:55 am | Question-and-Answer Session |
| 9:00 am | Future Approaches to the Treatment of Locally Advanced NSCLC: Role of Targeted Agents Henning Willers |
| 9:20 am | Question-and-Answer Session |
| 9:25 am | Panel Discussion |
| 9:50 am | Break |
| Case-Based Discussions on the Future of Adjuvant Therapy Moderator: Thomas Lynch |
|
| 10:05 am | Overview and Case Presentation Thomas Lynch |
| 10:15 am | Incorporation of Angiogenesis and EGFR Inhibitors Into Adjuvant Regimens Lecia Sequist |
| 10:30 am | What Will Be the Role of ERCC1 in Selecting Adjuvant Therapy? George Simon |
| 10:45 am | Clinical Significance of Recent Adjuvant Trial Updates Heather Wakelee |
| 11:00 am | Question-and-Answer Session |
| 11:10 am | Postsession Survey |
| 11:15 am | Roundtable Discussion Above Speakers |
| 11:45 am | Break to Serve Lunch |
| Future Approaches to the Treatment of Stage IV NSCLC Moderator: Thomas Lynch |
|
| 12:10 pm | Presession Survey |
| 12:15 pm | New Chemotherapeutic Options for Metastatic NSCLC Nasser Hanna |
| 12:35 pm | Question-and-Answer Session |
| 12:40 pm | Role of Histology in Treatment Outcome: How Will This Influence Therapy in 2009? Thomas Stinchcombe |
| 1:00 pm | Question-and-Answer Session |
| 1:05 pm | Application of EGFR Inhibitors in First- and Second-line Regimens Gregory Riely |
| 1:25 pm | Question-and-Answer Session |
| 1:30 pm | Angiogenesis Inhibitors in Lung Cancer: Where Do We Go From Here? Heather Wakelee |
| 1:50 pm | Question-and-Answer Session |
| 1:55 pm | Postsession Survey |
| 2:00 pm | Panel Discussion |
| 2:25 pm | Break |
| Upcoming Agents in Advanced Lung Cancer Moderator: Thomas Lynch |
|
| 2:40 pm | Attacking Tumor Vasculature, Including Vascular-Disrupting and Novel Antiangiogenic Agents Primo N. Lara, Jr |
| 2:50 pm | Question-and-Answer Session |
| 2:55 pm | Targeting the IGF-1R Axis Alan Sandler |
| 3:05 pm | Question-and-Answer Session |
| 3:10 pm | Epigenetic Approaches to the Treatment of Lung Cancer Suresh Ramalingam |
| 3:20 pm | Question-and-Answer Session |
| 3:25 pm | Inhibiting PI3K as a Therapeutic Strategy Jeffrey Engelman |
| 3:35 pm | Question-and-Answer Session |
| 3:40 pm | Treating Patients With Ras-Mutated Lung Cancer Alice Tsang Shaw |
| 3:50 pm | Question-and-Answer Session |
| 3:55 pm | Closing Remarks Thomas Lynch |
| 4:00 pm | Adjourn |
Educational Grants
An educational grant for this activity was provided by:
- Genentech BioOncology/
OSI Oncology - Merck Oncology
- AstraZeneca
Lilly Oncology - Bristol-Myers Squibb/
ImClone Systems